GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Debt-to-EBITDA

Evolus (FRA:EVL) Debt-to-EBITDA : -195.17 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evolus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.6 Mil. Evolus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €122.5 Mil. Evolus's annualized EBITDA for the quarter that ended in Dec. 2024 was €-0.6 Mil. Evolus's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -195.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Evolus's Debt-to-EBITDA or its related term are showing as below:

FRA:EVL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.36   Med: -1.71   Max: -0.37
Current: -5.2

During the past 10 years, the highest Debt-to-EBITDA Ratio of Evolus was -0.37. The lowest was -18.36. And the median was -1.71.

FRA:EVL's Debt-to-EBITDA is ranked worse than
100% of 680 companies
in the Drug Manufacturers industry
Industry Median: 1.62 vs FRA:EVL: -5.20

Evolus Debt-to-EBITDA Historical Data

The historical data trend for Evolus's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Debt-to-EBITDA Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.96 -1.91 -1.23 -3.03 -5.20

Evolus Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.16 -4.65 -6.30 -2.50 -195.17

Competitive Comparison of Evolus's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evolus's Debt-to-EBITDA falls into.


;
;

Evolus Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evolus's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.641 + 122.489) / -23.876
=-5.20

Evolus's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.641 + 122.489) / -0.636
=-195.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Evolus  (FRA:EVL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Evolus Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Evolus's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines